Zonulin Family Peptide Test · Stool

Your gut is lined with a single layer of cells held together by seals called tight junctions. When those seals loosen, molecules that should stay inside your intestine can slip through into your bloodstream and stir up low-grade inflammation. This test looks at a family of proteins in your stool tied to how those seals open and close.

ZFP (zonulin family peptide) is a newer research marker, not a polished clinical test. The signal is real but imperfect: the lab assay detects a group of related proteins rather than a single molecule, and the exact meaning of any one reading is still being worked out. It is most useful as a baseline you track over time, especially if you are dealing with gut symptoms, autoimmunity, or a diet change you want to measure the effect of.

What This Test Actually Measures

The original target protein, called zonulin, is identical to a liver-derived precursor (pre-haptoglobin-2) and is the only known human protein shown to reversibly loosen tight junctions between gut cells. When it is released, usually in response to gluten exposure or imbalanced gut bacteria, the seals between intestinal cells briefly relax and the gut becomes more permeable.

The twist is that the widely used commercial stool and blood assays do not cleanly detect pre-haptoglobin-2. Laboratory analysis shows they bind a group of structurally similar proteins, most likely including properdin, part of the immune system's complement pathway. That is why this test is now labeled zonulin family peptide rather than zonulin alone. The reading is best thought of as a broader barrier-and-inflammation signal rather than a single, precisely defined molecule.

Why a Leaky Gut Barrier Matters

Increased intestinal permeability shows up across many conditions where inflammation and immune dysregulation drive disease, including celiac disease, inflammatory bowel disease, type 1 diabetes, rheumatoid arthritis, severe asthma, obesity, insulin resistance, and hypertension. The theory is that when the gut seal leaks, bacterial fragments and food-derived molecules cross into the bloodstream and keep the immune system in a constant low simmer.

In celiac disease, ZFP release is a known response to gluten. In broader populations, higher levels tend to cluster with worse metabolic profiles: bigger waists, higher blood pressure, higher fasting glucose, and higher triglycerides. The pattern suggests that whatever this assay is capturing, it tracks systemic inflammatory and metabolic stress rather than gut disease alone.

Celiac Disease and Gluten Exposure

Fecal zonulin is higher in children with active celiac disease than in healthy peers and drops substantially once they start a gluten-free diet. This makes stool ZFP one of the few non-invasive signals that can reflect whether the gut is still reacting to gluten, even when blood antibodies look fine. It is being studied as a way to monitor silent gluten exposure in people who should be off gluten entirely.

Inflammatory Bowel Disease

In pediatric Crohn's disease and ulcerative colitis, fecal zonulin levels are higher than in controls and correlate with disease activity and with fecal calprotectin, the most established stool inflammation marker. The two markers tend to move together, but they are not redundant: calprotectin reflects neutrophil-driven inflammation, while ZFP reflects barrier integrity. In ulcerative colitis, anti-TNF therapy improves both.

Type 1 Diabetes and Autoimmune Risk

Roughly 40 percent of people with type 1 diabetes have elevated blood zonulin, and relatives who go on to develop the disease often show rising levels years before diagnosis. In one cohort of people at genetic risk, elevated zonulin preceded a type 1 diabetes diagnosis by an average of about 3.5 years. This has led to the hypothesis that gut barrier disruption is one of the upstream events that sets the stage for the autoimmune attack on pancreatic cells. Evidence here comes mainly from serum measurement; whether stool ZFP tracks the same process as closely has not been directly confirmed.

Rheumatoid Arthritis Risk

In people who test positive for anti-citrullinated protein antibodies (ACPA) but have not yet developed joint disease, serum ZFP is higher than in ACPA-negative peers. In some cohorts, higher ZFP modestly predicts progression to clinical arthritis; in others it does not. Taken together, the data suggest gut barrier dysfunction may contribute to the autoimmune process that precedes rheumatoid arthritis, but the marker is not yet strong enough to drive individual decisions.

Metabolic Health and Cardiovascular Risk

Elevated serum zonulin has been linked to obesity, insulin resistance, non-alcoholic fatty liver disease, coronary artery disease, and higher blood pressure in independent cohorts. In a large Swedish cohort, higher serum zonulin tracked more closely with obesity and high lipids than with gastrointestinal symptoms. In obese children, levels climb with BMI and with insulin resistance. In coronary artery disease, zonulin levels are higher than in healthy controls and may contribute to bacterial products entering circulation. The serum-based evidence is stronger than stool-specific data for these associations.

Other Conditions Where Levels Run High

Elevated zonulin has been reported in several additional settings: active multiple sclerosis (where it tracks with brain MRI findings), severe asthma (where it may distinguish severe from non-severe disease), systemic lupus erythematosus (where it inversely tracks with complement C3), irritable bowel syndrome (where serum levels are as high as in celiac disease and correlate with stool frequency in the diarrhea-predominant form), fibromyalgia, chronic fatigue syndrome, colorectal cancer, and severe COVID-19, where higher admission levels independently predicted mortality in one cohort. Most of this evidence uses serum rather than stool measurement.

When Lower Levels Are Not Necessarily Better

This is not a simple more-is-bad marker. In advanced liver disease, low zonulin reflects the failing liver's inability to produce the precursor protein, not a healthier gut. In advanced diabetic kidney disease, levels are lower than in diabetics with healthy kidneys and track with worse kidney outcomes. After colorectal surgery, ZFP drops sharply within days regardless of whether complications develop. The safest interpretation is a framework one: this marker reflects a phenotype tied to barrier dynamics, liver synthesis, and systemic inflammation, and the same number can have different meanings depending on what else is going on in the body.

Reference Ranges: What the Research Shows

There is no standardized clinical cutpoint for stool ZFP. No guideline body has defined a normal range, an optimal range, or a threshold for action. Assay manufacturers publish their own reference intervals, and these can shift between kit versions. Published research values come mostly from serum studies in specific populations and use different units than the stool assay. The ranges below are drawn from studies that reported fecal or serum ZFP in defined groups and are useful only as orientation, not as targets.

These values come from distinct populations, assays, and specimen types (some serum, some stool). They are illustrative only. Your lab will report its own reference interval, likely in different units, and that is the number you should compare against over time.

Source: Carrera-Bastos et al., 2018 (serum); Martinez Gallego et al., 2024 (stool, celiac); Szymańska et al., 2021 (stool, IBD). What this means for you: rather than trying to hit a number, use your own baseline as the reference. Compare future readings to your first result using the same lab and assay.

Why One Reading Is Not Enough

Single ZFP readings bounce around more than well-established clinical markers. Levels respond to recent gluten exposure, acute illness, surgery, and shifts in the gut bacteria, any of which can move the number over days to weeks. Commercial assays also have meaningful between-run variability (around 13 to 14 percent in reported kit data), which means two readings a few points apart may not reflect a real biological change. One-off abnormal results in a person with no symptoms are easy to over-interpret.

Because of this variability, tracking your own trend is more useful than comparing against a population reference. A reasonable cadence: get a baseline now, retest in 3 to 6 months if you are making a targeted change (gluten-free diet, polyphenol-rich diet, probiotics, treatment of a gut condition), and then at least annually. Always use the same lab for consistency, since assays are not interchangeable between manufacturers.

When Results Can Be Misleading

A single ZFP reading can shift for reasons that have nothing to do with long-term barrier health. The most useful thing to know before interpreting a number is what else is going on in your body right now.

• Acute illness, infection, or recent surgery: levels can swing sharply in either direction during and shortly after an acute event, with a sharp post-surgical drop documented in the first few days after colorectal surgery.
• Recent gluten exposure or a large, unusual meal: the marker can respond to short-term dietary shifts, which means your baseline should be taken during a typical week of eating, not after a celebration weekend.
• Assay differences between labs: commercial ELISA kits detect a mix of related proteins and can give meaningfully different numbers for the same sample. Always use the same lab for serial testing.
• Advanced liver or kidney disease: a low reading in someone with cirrhosis or advanced diabetic kidney disease may reflect organ dysfunction rather than a healthy gut barrier.

What to Do If Your Result Is Elevated

An isolated high reading is a signal to investigate, not a diagnosis. The most useful companion tests depend on your symptoms and history. If you have digestive symptoms, pair ZFP with fecal calprotectin (the best-validated stool inflammation marker) to distinguish barrier stress from active gut inflammation. If you have a family history of celiac disease or unexplained iron deficiency, anemia, or skin rash, add celiac antibody testing (tTG IgA). If you have metabolic concerns, look at fasting insulin, hs-CRP (a marker of systemic inflammation), and markers of liver health. If you have autoimmune risk factors, the marker is best interpreted in the context of condition-specific antibody panels.

A consistently elevated trend alongside either gut symptoms or positive companion tests is worth working up with a gastroenterologist, especially if you have not had celiac disease ruled out. A single high reading in someone with no symptoms and normal companion tests is most useful as a baseline to retest after a targeted intervention.